TPL Path Labs has been sold to the US-based laboratory network StageBio, successfully continuing the company's growth story.
TPL, established 2008, is a contract research laboratory (CRO) with deep expertise, a broad range of methods and a long-standing customer base. For pharmaceutical companies, international CROs, biotech and medtech companies, histopathological and molecular pathological analyses are performed according to GLP/GCLP standards supporting preclinical and clinical studies. TPL provides a complete offering, starting with necropsy services on site, followed by histological processing and pathological analysis of the tissue samples. Methods include immunohistochemistry; cutting & grinding of fixated tissue; ISH; FISH; digital imaging and tissue cross-reactivity (monoclonal antibody studies).
StageBio is one of the leading providers of GLP-compliant necropsy, histology and pathology services as well as sample archiving. The company is headquartered in Mt Jackson (Virgina, USA) and comprises seven additional locations in the USA. In total, StageBio employs more than 200 staff, among them over 30 pathologists. Since 2018 StageBio has been a portfolio company of Ampersand Capital (Wellesley MA, USA).
The acquisition of TPL will enable StageBio to expand its service portfolio and take an important step into the European market.
"It is very gratifying to see that the business I initiated is now being continued by StageBio and the team around Ayse Bal has found a new platform with excellent development opportunities. This also creates an excellent combination for our customers," said Dr. Helmut Laaff, founder and former owner of TPL. "I would also like to thank the Taurus team, who have been a great support to me at all times throughout this process and through the challenging Covid times".
Contact persons for this transaction
We are also available to accompany your next M&A project